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Merkel cell carcinoma (MCC) is an aggressive
neuroendocrine skin cancer thought to be derived
from Merkel cells present in the cutaneous basement
layer; these cells have synaptic contacts with
somatosensory afferents. MCC is a rare malignant
tumor, the development of which may be associated
with immunosuppressive conditions.1 Tofacitinib is
a Janus kinase (JAK) inhibitor that exerts anti-
inflammatory activity by inhibiting JAK enzymes,
thereby interfering with the JAK signal transducers
and activator of transcription (STAT) signaling
pathway. Tofacitinib is recommended for individuals
with active moderate-to-severe rheumatoid arthritis
(RA) that show an inadequate response to traditional
disease-modifying antirheumatic drugs or biologic
agents.2 Here we report a case of MCC in an RA
patient thought to be caused by immunosuppression
during treatment with tofacitinib.Fig 1. Merkel cell carcinoma that developed on the
posterior surface of the left thigh during treatment with
the oral JAK inhibitor, tofacitinib.CASE REPORT
A 66-year-old woman with refractory RA
previously treated with disease-modifying antirheu-
matic drugs (methotrexate, d-penicillamine, and
salazosulfapyridine) received monotherapy with
tofacitinib (5 mg/d) from December 2009. In May
2012, she contracted herpes zoster, which was
treated successfully with intravenous acyclovir. In
April 2013, a reddish, elastic, hard, and dome-shaped
nodule appeared on the posterior surface of the left
thigh, which grew to the size of a walnut after
4 months (Fig 1). Histologic analysis found densely
proliferating small round cells with numerousthe Department of Dermatology, Nagasaki University
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(Fig 2, A and B). The tumor cells stained positive for
cytokeratin 20, chromogranin A, and Merkel cell
polyomavirus (MCPyV) large T antigen but were
negative for thyroid transcription factor 1 (Fig 2,
C and D). Thus, the cutaneous neoplasm was
diagnosed as MCC. Treatment with tofacitinib was
discontinuedwith no alternative antirheumatic drugsJAAD Case Reports 2017;3:498-500.
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Fig 2. Histopathologic examination of the tumor. A, Hematoxylin-eosin staining found
proliferation of tumor cells within the dermis. B, Small, round basophilic cells are arranged
in cordlike structures. C and D, Immunohistochemical analysis found that the tumor
was positive for (C) cytokeratin 20 and (D) MCPyV large T antigen. (Original magnifications:
A, 340; B, 3400.)
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metastasis to internal organs or lymph nodes. The
tumor was surgically excised with a 2-cm margin. A
sentinel lymph node biopsy found metastasis to 1
lymph node. Therefore, the left inguinal lymph
nodes were dissected, which found no other metas-
tasis in lymphoid tissue. Adjuvant therapy comprised
irradiation (60 G) of the primary and left inguinal
lesions. Four years after treatment, there are no signs
of local recurrence or metastasis, even after resump-
tion of tacrolimus treatment for recurrent arthritis. In
addition, the patient had no other skin neoplasms
before and during treatment with JAK inhibitor or
tacrolimus.DISCUSSION
MCCs are characterized according to the acronym
AEIOU: asymptomatic/lack of tenderness, expanding
rapidly (\3 months), immunosuppression, older than
50 years, and ultraviolet-exposed location.3 Among
these, immunosuppressive conditions (including he-
matologic malignancies, acquired immune deficiency
syndrome, solid organ transplants, and autoimmune
disease) are associated with an increased risk
of MCC development.1 Indeed, immunosuppressedindividuals make up approximately 10% of MCC
patients and show poorer MCC-specific survival.4
This patient was positive for MCPyV large
T antigen, which is present in about 80% of MCCs
and is thought to be a link between MCC and
immunosuppression. Although most individuals are
naturally exposed to MCPyV, very few go on to have
MCC.5 Therefore, other factors such as an
immunosuppressed state contribute to viral
integration, mutagenesis, and carcinogenesis.6
Other tumors caused by viruses include Kaposi
sarcoma and Burkitt lymphoma; both are more
prevalent in immunodeficient patients.7 However,
it is unclear whether MCPyV affects the proliferation
of MCC or patient survival.
Tofacitinib is an oral synthetic small molecule
drug used to treat RA. It acts by inhibiting JAK1 and
JAK3, thereby interfering with the JAK-STAT
signaling pathway and blocking production of
interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21. A
previous study concluded that the age- and
sex-adjusted standardized incidence ratio for
all malignancies, excluding nonmelanoma skin
cancer, among tofacitinib-treated RA patients was
not elevated.8 However, we believe that this
patient had MCC caused by tofacitinib-induced
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with tofacitinib alone and (2) the back of the thigh is
an unusual site for MCC, as it is usually shielded from
ultraviolet irradiation. Additionally, It was found that
phosphorylated-STAT3 signaling had an association
with development of MCC and survival of patients.9
Previous studies report MCC associated with tumor
necrosis factor inhibitors.10,11 JAK inhibitors and
several biological agents are relatively new
treatments, so it is unclear whether they have the
potential to drive development of MCC; therefore, it
is important to gather more MCC cases occurring in
individuals treated with these immunosuppressive
agents.
The authors thank Dr Fumi Toriyama for providing the
antibody specific for the MCPyV large T antigen.
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